Filing Flows › Health Care › Ovid Therapeutics (OVID)
Ovid Therapeutics (OVID) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Ovid Therapeutics (OVID) Q2 2026 earnings results →
Q2 2026 Revenue down 88% year over year to $733K
Ovid Therapeutics made $733K in Q2 2026 (-88% Y/Y). Operating margin n/m, net loss $15.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $733K in Q2 2026, down 88% year over year.
Operating costs exceeded revenue by $15.7M, an operating margin of -2141.6%. Total costs grew 45% against a revenue fall of 88%. The fastest-growing cost line was Research & development (+54%). The quarter ended with a net loss of $15.0M.
Operating cash flow was −$17.6M. Non-cash charges added back $16K of depreciation and amortization and $1.4M of share-based compensation. Working capital and other items used $4.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $733K | -88% | n/m | −$15.0M | −$17.6M |
| Q4 2025 | 10-K | Mar 18, 2026 | $718K | +845% | n/m | $9.7M | −$10.4M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $132K | -24% | n/m | −$12.2M | −$12.9M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $6.3M | 37× | -80.9% | −$4.7M | −$4.8M |
| Q1 2025 | 10-Q | May 13, 2025 | $130K | -12% | n/m | −$10.2M | −$10.3M |
| Q4 2024 | 10-K | Mar 11, 2025 | $76K | -46% | n/m | −$9.3M | −$10.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Ovid Therapeutics
Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system (“CNS”) are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms. We seek to address fundamental biological targets in the brain that are implicated in neuronal hyperexcitability, such as neurotransmitters and dysregulated ion channels. By mitigating excessive neuronal hyperexcitation with differentiated medicines, we believe we can unlock substantial scientific, therapeutic and commercial opportunities across a range of neurological and psychiatric conditions that have few therapeutic options today, both impacting patients’ lives and creating long-term stockholder value.
In its own words, from its 10-K, filed Mar 18, 2026.
Ovid Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -88% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| OVID Ovid Therapeutics | Q2 2026 | $733K | -88% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Ovid Therapeutics 10-Q on SEC EDGAR · CIK 1636651 · Pharmaceutical Preparations
13F: who owns OVID and who is buying
More on OVID
History
Every quarter: Q2 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results